Last reviewed 2026-04-22 · How we verify

Tacrolimus, Reddy Laboratory

Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors.

Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Atopic dermatitis, Severe rheumatoid arthritis.

At a glance

Mechanism of action

Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for T-cell receptor signaling. By blocking calcineurin, tacrolimus prevents dephosphorylation and nuclear translocation of NFAT, thereby suppressing the transcription of IL-2 and other cytokines required for T-cell proliferation and immune response.

Approved indications

• Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)
• Atopic dermatitis
• Severe rheumatoid arthritis
• Autoimmune uveitis

Common side effects

• Nephrotoxicity
• Hypertension
• Hyperglycemia/new-onset diabetes
• Neurotoxicity (tremor, headache)
• Infections
• Hyperkalemia
• Gum hyperplasia

Key clinical trials

• Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tacrolimus, Reddy Laboratory CI brief — competitive landscape report
• Tacrolimus, Reddy Laboratory updates RSS · CI watch RSS
• University of Cincinnati portfolio CI